{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:09:16Z","timestamp":1780362556226,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Mantle cell lymphoma (MCL) represents a group of highly heterogeneous tumors, leading to a poor prognosis. Early prognosis prediction may guide the choice of therapeutic regimen. Thus, the purpose of this study was to investigate the potential application value of heterogeneity index (HI) in predicting the prognosis of MCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 83 patients with histologically proven MCL who underwent baseline fluorine-18-fluorodeoxyglucose positron emission tomography\/computed tomography (<jats:sup>18<\/jats:sup>F-FDG PET\/CT) were retrospectively enrolled. The clinicopathologic index and PET\/CT metabolic parameters containing maximum and mean standard uptake value (SUV<jats:sub>max<\/jats:sub> and SUV<jats:sub>mean<\/jats:sub>), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and HI were evaluated. Receiver operating characteristic (ROC) curve analyses were performed to determine the optimal cutoff values of the parameters for progression-free survival (PFS) and overall survival (OS). Univariate and multivariate Cox regression were used to assess relationships between risk factors and recurrence. Kaplan\u2013Meier plots were applied for survival analyses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In univariate analyses, age [HR = 2.51, 95% CI = 1.20\u20135.24, <jats:italic>p<\/jats:italic> = 0.041 for body weight (BW)] and HI-BW (HR = 4.17, 95% CI = 1.00\u201317.38, <jats:italic>p<\/jats:italic> = 0.050) were significantly correlated with PFS. In multivariate analyses, age (HR = 2.61, 95% CI = 1.25\u20135.47, <jats:italic>p<\/jats:italic> = 0.011 for BW) and HI-BW (HR = 4.41, 95% CI = 1.06\u201318.41, <jats:italic>p<\/jats:italic> = 0.042) were independent predictors for PFS, but not for OS. B symptoms (HR = 5.00, 95% CI = 1.16\u201321.65, <jats:italic>p<\/jats:italic> = 0.031 for BW) were an independent prognostic factor for OS, but not for PFS. The other clinicopathologic index and PET\/CT metabolic parameters were not related to outcome survival in MCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The age and HI derived from baseline PET\/CT parameters were significantly correlated with PFS in MCL patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.862473","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:08:53Z","timestamp":1649930933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET\/CT in Mantle Cell Lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Fei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxin","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoli","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21357","article-title":"2016 Us Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392","article-title":"Update on Mantle Cell Lymphoma","volume":"132","author":"Maddocks","year":"2018","journal-title":"Blood"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.01.018","article-title":"(18)F-FDG PET or Pet\/Ct in Mantle Cell Lymphoma","volume":"20","author":"Albano","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B5","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular Pathogenesis of Mantle Cell Lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24797","article-title":"Mantle Cell Lymphoma: 2017 Update on Diagnosis, Risk-Stratification, and Clinical Management","volume":"92","author":"Vose","year":"2017","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331","article-title":"A New Prognostic Index (Mipi) for Patients With Advanced-Stage Mantle Cell Lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"Sox11 and Tp53 Add Prognostic Information to Mipi in a Homogenously Treated Cohort of Mantle Cell Lymphoma\u2013a Nordic Lymphoma Group Study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-584193","article-title":"Mir-18b Overexpression Identifies Mantle Cell Lymphoma Patients With Poor Outcome and Improves the Mipi-B Prognosticator","volume":"125","author":"Husby","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.223016","article-title":"Prognostic Value of Fdg-Pet in Patients With Mantle Cell Lymphoma: Results From the Lyma-Pet Project","volume":"105","author":"Bailly","year":"2020","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1469-2","article-title":"Prognostic Impact of 18f-Fluoro-Deoxyglucose Positron Emission Tomography in Untreated Mantle Cell Lymphoma: A Retrospective Study From the Goelams Group","volume":"37","author":"Bodet-Milin","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22126","article-title":"Utility of Positron Emission Tomography Scans in Mantle Cell Lymphoma","volume":"86","author":"Hosein","year":"2011","journal-title":"Am J Hematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-019-01354-9","article-title":"Prognostic Role of Baseline 18f-Fdg Pet\/Ct Metabolic Parameters in Mantle Cell Lymphoma","volume":"33","author":"Albano","year":"2019","journal-title":"Ann Nucl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487","article-title":"Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management","volume":"94","author":"Jain","year":"2019","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002385","article-title":"Coding and Noncoding Drivers of Mantle Cell Lymphoma Identified Through Exome and Genome Sequencing","volume":"136","author":"Pararajalingam","year":"2020","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging Therapies in Mantle Cell Lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04411-7","article-title":"Prognostic and Theranostic 18f-Fdg Pet Biomarkers for Anti-Pd1 Immunotherapy in Metastatic Melanoma: Association With Outcome and Transcriptomics","volume":"46","author":"Seban","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-3975-6","article-title":"Preoperative [(18)F]FDG PET\/CT Tumour Heterogeneity Index in Patients With Uterine Leiomyosarcoma: A Multicentre Retrospective Study","volume":"45","author":"Lee","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-018-4134-9","article-title":"Pet-Based Prognostic Survival Model After Radiotherapy for Head and Neck Cancer","volume":"46","author":"Castelli","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0001","article-title":"Pretreatment (18)F-Fdg Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients With Metastatic Triple-Negative Breast Cancer","volume":"23","author":"Gong","year":"2018","journal-title":"Oncologist"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: Eanm Procedure Guidelines for Tumour Imaging: Version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2314-6","article-title":"Evaluation of Intratumoural Heterogeneity on \u00b98f-FDG PET\/CT for Characterization of Peripheral Nerve Sheath Tumours in Neurofibromatosis Type 1","volume":"40","author":"Salamon","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib Plus Venetoclax for the Treatment of Mantle-Cell Lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33108-2","article-title":"Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (Ace-Ly-004): A Single-Arm, Multicentre, Phase 2 Trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.06.001","article-title":"What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes","volume":"34","author":"Witzig","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2020.0073","article-title":"Single-Cell Rna-Seq Reveals the Immune Escape and Drug Resistance Mechanisms of Mantle Cell Lymphoma","volume":"17","author":"Wang","year":"2020","journal-title":"Cancer Biol Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-014-0268-5","article-title":"Pretreatment (18)F-Fdg Uptake Heterogeneity Can Predict Survival in Patients With Locally Advanced Nasopharyngeal Carcinoma\u2013a Retrospective Study","volume":"10","author":"Yang","year":"2015","journal-title":"Radiat Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000001587","article-title":"The Assessment of Estrogen Receptor Status and Its Intratumoral Heterogeneity in Patients With Breast Cancer by Using 18f-Fluoroestradiol PET\/Ct","volume":"42","author":"Yang","year":"2017","journal-title":"Clin Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4274\/mirt.94914","article-title":"The Correlation Between Pre-Treatment Fluorodeoxyglucose Positron Emission Tomography\/Computed Tomography Parameters and Clinical Prognostic Factors in Pediatric Hodgkin Lymphoma","volume":"26","author":"Tatc\u0131","year":"2017","journal-title":"Mol Imaging Radionucl Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guideline for the Management of Mantle Cell Lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21147\/j.issn.1000-9604.2017.01.08","article-title":"Peg-Asparaginase in Bfm-90 Regimen Improves Outcomes in Adults With Newly Diagnosed Lymphoblastic Lymphoma","volume":"29","author":"Zheng","year":"2017","journal-title":"Chin J Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-018-2526-z","article-title":"Tumor Long-Axis Diameter and Suvmax Predict Long-Term Responders in 90y-Ibritumomab Tiuxetan Monotherapy","volume":"109","author":"Tsukamoto","year":"2019","journal-title":"Int J Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2020.123","article-title":"Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18f-Fdg Pet-Ct Predict Outcomes in T-Cell Lymphoblastic Lymphoma","volume":"53","author":"Feng","year":"2021","journal-title":"Cancer Res Treat"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1515\/raon-2016-0045","article-title":"Prognosis Estimation Under the Light of Metabolic Tumor Parameters on Initial Fdg-Pet\/Ct in Patients With Primary Extranodal Lymphoma","volume":"50","author":"Okuyucu","year":"2016","journal-title":"Radiol Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-017-3766-5","article-title":"The Role of F-18 Fdg PET\/CT in Evaluating the Impact of Hiv Infection on Tumor Burden and Therapy Outcome in Patients With Hodgkin Lymphoma","volume":"44","author":"Lawal","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-019-01329-2","article-title":"Pre-Therapeutic Total Lesion Glycolysis on [(18)F]FDG-PET Enables Prognostication of 2-Year Progression-Free Survival in Malt Lymphoma Patients Treated With CD20-Antibody-Based Immunotherapy","volume":"21","author":"Mayerhoefer","year":"2019","journal-title":"Mol Imaging Biol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/hon.2563","article-title":"Prognostic Role of Baseline (18) F-FDG PET\/CT Parameters in Malt Lymphoma","volume":"37","author":"Albano","year":"2019","journal-title":"Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.862473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T10:08:55Z","timestamp":1649930935000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.862473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":39,"alternative-id":["10.3389\/fonc.2022.862473"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.862473","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"article-number":"862473"}}